

Paul S. Regier, Ph.D.

Dr. Paul S. Regier is a Post-doctoral Fellow at the Center for Studies on Addiction in the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine. His strong interest in the clinical problem of addiction evolved during his preclinical graduate work at the University of Minnesota, where he received a Ph.D. in neuroscience. There, his main research interests included characterizing relevant phenotypes vulnerable to addiction, using the tools of both neurobiology and behavioral pharmacology. This work led Dr. Regier to human imaging (fMRI) research as a natural translation of his preclinical interest in addiction and relapse vulnerability phenotypes. His over-arching goal is the development of treatments tailored to specific addiction phenotypes, embracing clinical heterogeneity within the addiction population as a potentially powerful clinical research tool. During his NIDA T32 Fellowship with Dr. Anna Rose Childress, Dr. Regier uncovered an adversity-driven, cue-vulnerable phenotype that has stimulated his ongoing individual and collaborative research efforts. His collaborative (pending) R01 proposes GABA-B agonism as a tailored treatment for cocaine patients with prior adversity (e.g., physical, sexual, and/or emotional abuse). Dr. Regier has authored and co-authored several publications in the field of addiction, and his research has been recognized by selection for a press conference at SfN, and by travel awards to CPDD.